Details

Autor(en) / Beteiligte

• Tatsuno, Saori
• Doi, Hiroshi
• Inada, Masahiro
• Uehara, Takuya
• Wada, Yutaro
• Ishikawa, Kazuki
• Tanaka, Kaoru
• Kitano, Mutsukazu
• Nishimura, Yasumasa

Titel

Clinical outcomes and failure patterns after postoperative radiotherapy for oral cavity squamous cell carcinoma

Ist Teil von

• Strahlentherapie und Onkologie, 2024-05, Vol.200 (5), p.389-399

Ort / Verlag

Berlin/Heidelberg: Springer Berlin Heidelberg

Erscheinungsjahr

2024

Link zum Volltext

Quelle

SpringerLink (Online service)

Beschreibungen/Notizen

• Purpose This study aimed to assess recurrence patterns and identify the optimal dose and target volumes of postoperative radiotherapy (PORT) in patients with oral cavity squamous cell carcinoma (OSCC). Methods Data of 111 patients who received PORT for OSCC between January 2010 and April 2020 were retrospectively reviewed. The median age was 68 years (range 19–88). PORT was administered as initial treatment to 63 patients and as salvage treatment for recurrent tumors to 48 patients. The median prescribed dose was 60 Gy (range 50–66) administered in 30 fractions (range 25–33). Results Median follow-up time was 73 months (range 24–147). Overall survival (OS), progression-free survival (PFS), local control (LC), and locoregional control (LRC) at 3 years were 55.6%, 45.6%, 74.6%, and 63.1%, respectively. There were no significant differences in OS, PFS, LC, and LRC between the initially diagnosed and postoperative recurrent cases. Of 22 patients (20%) who developed regional nodal recurrences, 17 (15%) and 11 (10%) had in-field and out-of-field recurrences, respectively. Of 105 patients who received irradiation to the primary tumor bed, 24 (23%) developed recurrence at the primary site. The PFS and LC rates were significantly worse in patients receiving ≤ 56 Gy to the primary site than those receiving > 56 Gy ( p  = 0.016 and p  = 0.032, respectively). Conclusion PORT was effective for postoperative recurrences as well as for initially diagnosed oral cavity cancer. Doses greater than 56 Gy to the primary site may be required in PORT for OSCC.